1. Sweden Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
Active Biotech AB

Active Biotech AB

ACTI.ST
Active Biotech ABSE flagStockholm Stock Exchange
5.45
SEK
-0.20
- -
143.67MMarket Cap
Active Biotech AB
ACTI.ST
(Stockholm Stock Exchange)

Recent

price

5.45

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
3.14
59.6
57.54
25.95
2.45
3.49
4.08
4.3
3.78
0.75
1.23
- -
- -
- -
- -
- -
- -
Revenue per Share
-61.13
-24.95
-45.96
-50.89
-54.6
-41.55
-12.76
-23.09
-6.96
-7.26
-5.91
-7.5
-8.04
-6.04
-7.44
-2.77
-1.87
Basic EPS, GAAP
-54.31
-12.53
-63.14
-24.55
-63.44
-46.78
-15.67
-9.86
-7.67
-7.62
-5.91
-6.95
-7.59
-6.04
-7.63
-2.4
-1.68
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
-644.48
-636.71
-679.13
-665.46
-694.75
-673.5
-678.76
-695.26
-625.13
-693.28
-603
-502.49
-467.95
-454.11
-656.09
-260.25
- -
Book Value per Share
50.26
132.46
89.27
97.28
95.58
38.77
39.11
16.48
16.59
11.44
4.05
7.02
4.72
4.01
6.13
4.11
2.53
Tangible Book Value per Share
4
4
4
4
4
5
5
5
5
5
5
7
7
8
5
13
19
Basic Weighted Avg Shares
11
226
219
108
10
16
19
20
20
4
7
- -
- -
- -
- -
- -
- -
Sales/Revenue/Turnover
-2,016.25
-48.56
-78.52
-200.52
-2,196.94
-1,093.25
-289.49
-243.4
-148.83
-1,051.3
-480.39
- -
- -
- -
- -
- -
- -
Operating Margin (%)
10
12
13
13
12
12
12
57
- -
1
1
1
1
2
2
2
- -
Depreciation Expense
-221
-95
-175
-212
-232
-194
-60
-109
-37
-34
-32
-50
-58
-46
-39
-37
-35
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
-1,946.68
-41.86
-79.88
-196.11
-2,226.29
-1,189.13
-312.91
-537.36
-183.92
-965.27
-479.48
- -
- -
- -
- -
- -
- -
Profit Margin (%)
65
354
187
248
246
67
61
76
87
53
21
46
32
28
30
53
45
Working Capital
242
235
228
224
223
216
207
- -
- -
2
1
- -
4
3
2
- -
- -
LT Debt
182
502
340
405
405
181
183
78
88
54
22
47
35
31
33
56
47
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
ST Debt
- -
2
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
16
26
26
Market Capitalization
219
73
102

Working Capital

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
Total Current Assets
14
68
56
Cash, Cash Equivalents & STI
9
65
53
Accounts Receivable, Net
5
2
3
Inventories
- -
- -
- -
Total Current Liabilities
12
14
11
Payables & Accruals
- -
- -
- -
ST Debt
- -
2
- -
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
0.96%
30.1%
69.85%
Free Cash Flow
-12.32%
2.84%
-19.83%
Net Income, GAAP
-3.48%
6.18%
-5.27%
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-1.04
-1.05
-0.79
-1.36
-7.44
2025
-0.71
-0.72
-0.39
-0.54
-2.77
2026
-0.32
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Similar Companies
Lonza Group AG (0QNO.L)
ForU Holdings, Inc. (FORU)
Oncocross Co., Ltd. (382150.KQ)
iTeos Therapeutics, Inc. (ITOS)
LadRx Corporation (LADX)
NuCana plc (NCNA)
Business
Active Biotech AB (publ) is a Sweden-based biotechnology company specializing in the research, development, and production of pharmaceutical products focused on immunomodulatory treatments for oncology and inflammatory diseases. Its main products include small molecule immunomodulators such as tasquinimod and laquinimod, addressing hematological cancers, non-infectious uveitis, and solid tumors, alongside antibody-based immunotherapy represented by the partnered anti-cancer immunotherapy naptumomab with NeoTX Therapeutics. The company operates primarily in Sweden and collaborates internationally with academic and clinical partners in the US and Europe to advance its clinical programs. Founded in 1983 and headquartered in Lund, Sweden, Active Biotech's portfolio targets specialist indications with high medical need and commercial value. Recent major developments include the acquisition of exclusive rights to patents for tasquinimod in combination therapy for multiple myeloma, approval of a clinical trial for tasquinimod in myelofibrosis in Europe, and the start of enrollment for a clinical phase I study of a topical ophthalmic formulation of laquinimod. The company also completed a SEK 43.4 million rights issue in 2024 to support its clinical development activities and expanded its collaborations with institutions such as MD Anderson and Oncode Institute, while demonstrating clinical activity of naptumomab in non-small cell lung cancer. These advancements underline Active Biotech's strategic focus on innovative immuno-oncological and immunological therapies with significant unmet medical needs and projected commercial potential.